Form 144: Option exercises listed; Joseph Loscalzo sold shares (IONS)
A Form 144 filing for Ionis Pharmaceuticals (IONS) indicates proposed sales related to various option exercises and two insider dispositions by Joseph Loscalzo. The filing details multiple option-exercise issuances on different dates totaling specific share counts and records Loscalzo's sales of 832 shares for $66,833 on March 3, 2026, and 200 shares for $16,000 on March 4, 2026. This is a routine regulatory report, assessed as neutral in sentiment and impact.
APR 30·Insider Monkey▲
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2026 Earnings Call Transcript
Ionis Pharmaceuticals reported strong Q1 2026 financial results, exceeding earnings expectations with an EPS of $-0.56 against an expected $-0.85. The company highlighted accelerating demand for Tryngolza and strong early trajectory for DAWNZERA, leading to an increased annual peak sales estimate for olezarsen to over $3 billion. Ionis also updated its 2026 financial guidance, projecting total revenue between $875 million and $900 million due to robust commercial and R&D revenue streams.
APR 29·Investing.com▲
Oppenheimer raises Ionis Pharmaceuticals price target on guidance
Oppenheimer has increased its price target for Ionis Pharmaceuticals (NASDAQ:IONS) to $110 from $104, maintaining an Outperform rating, following the company's strong Q1 2026 results. Ionis raised its full-year 2026 revenue guidance to $875-$900 million, up from $800-$825 million, driven by product launches and collaboration revenue. The biotech firm also significantly increased its peak sales forecast for olezarsen in SHTG to over $3 billion in the United States.
